Tegaserod Maleate

Catalog No.S5401 Batch:S540101

Print

Technical Data

Formula

C16H23N5O.C4H4O4

Molecular Weight 417.46 CAS No. 189188-57-6
Solubility (25°C)* In vitro DMSO 83 mg/mL (198.82 mM)
Ethanol 8 mg/mL (19.16 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Tegaserod Maleate(HTF-919) is a hydrogen maleate salt form of tegaserod, which is a 5-HT4 receptor partial agonist and binds with high affinity to 5-HT4 receptors. It has limited affinity for 5-HT1 receptors and no appreciable affinity for other 5-HT receptors, muscarinic, adrenergic, dopaminergic or opiate receptors.
Targets
5-HT4 receptor [1]
In vitro

In guinea-pig and rat colon, luminal application of tegaserod activates 5-HT4 receptors on intrinsic primary sensory neurons that release calcitonin gene-related peptide which in turn activates cholinergic interneurons stimulating the peristaltic reflex. In isolated segments of guinea-pig colon, intralumnal tegaserod increased the velocity of propulsion of artificial faecal pellets through the stimulation of the same receptor. In rat distal colon, intraluminal tegaserod stimulated 5-HT4 4 receptors on colonocytes to secrete chloride and water through an adenylyl cyclase-dependent pathway[1].

In vivo

In a study in dogs tegaserod 0.1 or 0.3 mg/kg i.v. increased the motility of the antrum, duodenum and jejunum in both fasting and fed conditions. In a model of delayed gastric emptying, the same doses of tegaserod restored normal gastric transit time. Tegaserod 0.3 mg/kg in rats was able to increase gastric and small bowel motility while in a model of postoperative ileus it was able to restore gastric motility. In humans, pharmacokinetic analysis reveals that tegaserod is rapidly absorbed following oral administration. Absolute bioavailability is 11 ± 3% and is decreased by 50% under fed conditions. The time to reach peak plasma concentration ranges from 1-1.3 h. In the bloodstream, tegaserod is predominantly bound by α1-glycoprotein and does not cross the blood-brain barrier to any significant extent. The terminal elimination half time is 11 ± 5 h. Age and gender do not influence the pharmacokinetics of tegaserod and tegaserod has the potential for good tolerability[1].

Protocol (from reference)

Selleck's Tegaserod Maleate has been cited by 2 publications

Tegaserod Maleate Suppresses the Growth of Gastric Cancer In Vivo and In Vitro by Targeting MEK1/2 [ Cancers (Basel), 2022, 14(15)3592] PubMed: 35892850
Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway [ Front Oncol, 2021, 11:683241] PubMed: 34422635

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.